cyproheptadine has been researched along with milnacipran in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwamoto, Y; Yamawaki, S | 1 |
| Johnson, WG; Souayah, N; Yacoub, HA | 1 |
| Morphy, R; Rankovic, Z | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
3 review(s) available for cyproheptadine and milnacipran
| Article | Year |
|---|---|
[Serotonin syndrome].
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclopropanes; Cyproheptadine; Diagnosis, Differential; Fluvoxamine; Humans; Milnacipran; Reference Standards; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome | 2003 |
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cyproheptadine and milnacipran
| Article | Year |
|---|---|
Serotonin syndrome after administration of milnacipran for fibromyalgia.
Topics: Aged; Cyclopropanes; Cyproheptadine; Fibromyalgia; Humans; Male; Milnacipran; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome | 2010 |